Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (Details Textual)

STOCKHOLDERS' EQUITY (Details Textual) (USD $)	12 Months Ended		134 Months Ended	12 Months Ended		12 Months Ended		1 Months Ended		12 Months Ended		12 Months Ended					12 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012 Class B Warrants [Member]	Sep. 10, 2012 Class B Warrants [Member]	Dec. 31, 2013 Maximum [Member]	Dec. 31, 2013 Minimum [Member]	Feb. 28, 2013 February Offering One [Member]	Feb. 20, 2013 February Offering One [Member]	Dec. 31, 2013 February Offering Two [Member]	Feb. 20, 2013 February Offering Two [Member]	Dec. 31, 2013 February Offering [Member]	Dec. 31, 2013 June Public Offering [Member]	Dec. 31, 2012 June Public Offering [Member]	Dec. 31, 2012 June Public Offering [Member] Ninety Day Warrant [Member]	Dec. 31, 2012 June Public Offering [Member] Five Year Warrant [Member]	Dec. 31, 2012 June Public Offering [Member] Underwritten Offering [Member]	Dec. 31, 2013 November 2012 Private Placement [Member]	Dec. 31, 2012 November 2012 Private Placement [Member]	Dec. 31, 2012 November 2012 Private Placement [Member] Ninety Day Warrant [Member]	Dec. 31, 2012 November 2012 Private Placement [Member] Five Year Warrant [Member]
Class of Warrant or Right [Line Items]
Common stock, shares issued	57,397,997	46,397,997	57,397,997						11,000,000
Warrants Issued To Purchase Common Stock	5,500,000		5,500,000						11,000,000	8,000,000	5,500,000	770,000
Gross Proceeds From Issuance Of Common Stock Warrants								$ 5,500,000
Proceeds From Issuance Of Common Stock Warrants Net								4,975,153
Fair Value Of Warrants Classified As Derivative Liability	5,720,000	0	5,720,000
Derivative, Gain (Loss) on Derivative, Net, Total	(744,957)	0	(744,957)
Cash Fee Paid To Placement Agent												385,000
Warrants Exercise Price									$ 0.50	$ 1.00	$ 0.50	$ 0.625
Warrants Expiration Date	Feb. 20, 2014									Feb. 06, 2019		Feb. 04, 2018	Jun. 13, 2017				Jun. 13, 2017		Jan. 31, 2013
Change In Unrealized Gain Loss On Fair Value	2,365,000
Number Of Shares Issuable Upon Exercise Of Outstanding Warrants	36,782,459		36,782,459										2,981,440		5,420,800	2,710,400	271,040			2,000,000	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights													1.25		1.00	1.25	1.25		1.00	1.00	1.25
Stock Issued During Period, Shares, New Issues														5,420,800
Gross Proceeds From Issuance Of Common Stock														5,420,800					2,000,000
Proceeds From Issuance Of Common Stock	4,975,153	6,838,774	43,688,181											4,870,978
Relative Fair Value Of Warrants Issued														1,994,631					742,491
Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions, Total																	379,456
Fair Value Of Warrants Issued																	255,703
Warrants Amended To Purchase Common Stock					5,255,000														2,000,000
Deemed Dividend On Warrants	0	(543,359)	(543,359)	543,359
Proceeds From Warrant Exercises	0	1,088,300	1,338,300	1,088,300
Warrants Exercisable For Common Stock				4,332,500
Number Of Warrants Issued In Connection With Sale Of Common Stock																			2,000,000
Long Term Restricted Asset		2,000,000
Restricted Cash and Cash Equivalents	2,000,000		2,000,000															122,000
Reimbursement Of Administrative And Other Expenses																		40,000
Restricted Cash To Cash And Cash Equivalent																		$ 1,878,000
Warrants Unexercised	5,500,000
Resale Of Shares Of Common Stock	4,000,000
Percentage Of Liquidated Damages Per Month						5.00%	1.50%